Pediatric Tinea Versicolor Follow-up
- Author: Lyubomir A Dourmishev, MD, PhD; Chief Editor: Dirk M Elston, MD more...
Further Outpatient Care
Tinea versicolor tends to be associated with recurrences that must be properly treated.
Further Inpatient Care
No inpatient care is needed.
Inpatient & Outpatient Medications
Some authors recommend prophylaxsis with varying regimens of selenium sulfide shampoo or lotion.
Tinea versicolor is caused by M furfur, which is normally present on the skin surface and, therefore, is not considered a contagious disease. In past contaminated clothes and underwear were believed to play a role in disease transfer; however, climate factors, hyperhidrosis, sebum secretion, and genetic factors appear to be involved in disease pathogenesis.
Tinea versicolor has a high recurrence rate and may require frequent prophylactic treatment with intermittent topical or oral therapy.
Good personal hygiene may help limit recurrences. Specifically, patients should shower as soon as possible after participating in activities or exercise that produce significant perspiration.
The disease has benign course; however, it tends to have recurrences that must be properly treated. Some patients report for itching, burning and irritation of lesions. Severe depigmentation may cause significant psychological discomfort.
Prognosis is excellent. Although tinea versicolor is recurrent in some patients, the condition remains treatable.
Morbidity primarily results from the discoloration. The adverse cosmetic effect of lesions may lead to significant emotional distress, particularly in adolescents. Tinea versicolor frequently recurs despite adequate initial therapy. Even with adequate therapy, residual pigmentary changes may take several weeks to resolve.
The yeasts of the genus Malassezia have been associated with numerous other diseases that affect the human skin, such as Malassezia (Pityrosporum) folliculitis, seborrheic dermatitis, atopic dermatitis, psoriasis, confluent and reticulated papillomatosis, onychomycosis, and transient acantholytic dermatosis.
Tinea versicolor is caused by a fungus that is normally present on the skin surface and, therefore, is not considered a contagious disease. The disease causes no permanent sequelae, and any pigmentary alterations resolve entirely within a few months of adequate treatment. Effective therapy is available. Recurrences are common, and prophylactic therapy may be required.
Dourmishev AL. Pityriasis versicolor. Iliev B, Mitov G, Radev M. Infectology. Academic publishing house; 2001. 812-3.
Schmidt A. Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders. Cutis. 1997 Jan. 59(1):21-4. [Medline].
Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol. 2000 Oct. 38(5):337-41. [Medline].
Day T, Scurry J. Vulvar pityriasis versicolor in an immunocompetent woman. J Low Genit Tract Dis. J Low Genit Tract Dis. 2014 Jul;. 18(3):e71-3. [Medline].
Lodha N, Poojary SA. A Novel Contrast Stain for the Rapid Diagnosis of Pityriasis Versicolor: A Comparison of Chicago Sky Blue 6B Stain, Potassium Hydroxide Mount and Culture. Indian J Dermatol. 2015 Jul-Aug. 60(4):340-4. [Medline]. [Full Text].
Wigger-Alberti W, Elsner P. Fluorescence with Wood's light. Current applications in dermatologic diagnosis, therapy follow-up and prevention. Hautarzt. 1997 Aug. 48(8):523-7. [Medline].
[Guideline] Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb. 34(2 Pt 1):287-9. [Medline].
Muhammad N, Kamal M, Islam T, Islam N, Shafiquzzaman M. A study to evaluate the efficacy and safety of oral fluconazole in the treatment of tinea versicolor. Mymensingh Med J. 2009 Jan. 18(1):31-5. [Medline].
Cantrell WC, Elewksi BE. Can pityriasis versicolor be treated with 2% ketoconazole foam?. J Drugs Dermatol. 2014 Jul. 13(7):855-9. [Medline].
Gupta AK, Lyons DC. Pityriasis versicolor: an update on pharmacological treatment options. Expert Opin Pharmacother. 2014 Aug. 15(12):1707-13. [Medline].
Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg. 2014 Mar-Apr. 18(2):79-90. [Medline].
Abdul Bari MA. Comparison of Superficial Mycosis treatment using Butenafine and Bifonazole nitrate Clinical Efficacy. Glob J Health Sci. 2012 Nov 11. 5(1):150-4. [Medline].
Dehghan M, Akbari N, Alborzi N, Sadani S, Keshtkar AA. Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: A double-blind randomized controlled trial. J Dermatol. 2010 Aug. 37(8):699-702. [Medline]. [Full Text].
Shi VS, Lio PA. Diagnosis of pityriasis versicolor in paediatrics: the evoked scale sign. Arch Dis Child. 2011 Apr. 96(4):392-3. [Medline].